Concepedia

Vangelis Aktoudianakis

VA

Statistics

Publications

4

Citations

231

H-Index

4

Active since

2013

Affiliations

Gilead Sciences (United States)(Current)

Vangelis Aktoudianakis is an author at Gilead Sciences (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

2013–2020

4

Publications

4

Discovery of the First <i>C</i>-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients

Aesop Cho, Lijun Zhang, Jie Xu et al. · Journal of Medicinal Chemistry · 2013 · 128 citations

, , +17

Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B

Richard L. Mackman, Michael Mish, Gregory Chin et al. · Journal of Medicinal Chemistry · 2020 · 77 citations · Full text

, , +14

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

David Sperandio, Vangelis Aktoudianakis, Kerim Babaoglu et al. · Bioorganic & Medicinal Chemistry · 2018 · 16 citations · Full text

, , +11

In vitro and in vivo characterization of the selective toll-like receptor 8 agonist GS-9688

Stéphane Daffis, Dhivya Ramakrishnan, Chi‐Chien Niu et al. · Journal of Hepatology · 2017 · 10 citations

, , +16

1–4 of 4